Data underscores the potential of triple combination of BXCL701, NKTR-214 and an anti-PD1 agent as an anti- cancer therapy
NEW HAVEN, Conn; October 31, 2018-- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that the Company will present data on the combination of BTI’s BXCL701, Nektar Therapeutics’ NKTR-214 and an anti-PD1 across multiple tumor types at the upcoming Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting from November 7-11, 2018 in Washington, D.C.
Details of the poster are below:
Abstract #P368: Combination of a dipeptidyl peptidase inhibitor BXCL701 and biased CD122 agonist NKTR-214 with anti-PD1 provides functional immunological memory through inflammatory cell death
Date and Time: Friday, November 9th, 8 a.m. – 8 p.m. ET;
Saturday, November 10th, 8 a.m. – 8:30 p.m. ET
Session: Combination Therapy
Presenting Author: John MacDougall
About BioXcel Therapeutics, Inc. (BTI):
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxceltherapeutics.com.